Results 131 to 140 of about 3,103 (173)
Some of the next articles are maybe not open access.
Cabotegravir Plus Rilpivirine: First Approval
Drugs, 2020A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the ...
openaire +2 more sources
Cabotegravir and rilpivirine for the treatment of HIV
Expert Review of Anti-infective Therapy, 2020Introduction: Antiretroviral treatment (ART) has led to improved control of HIV infection, giving the opportunity of exploring therapeutic alternatives as new long-acting (LA) regimens, that might improve the quality of life of people living with HIV (PLWH).Areas covered: This article overviews the pharmacokinetic and pharmacodynamic properties of LA ...
David Rial-Crestelo +2 more
openaire +2 more sources
Cabotegravir long-acting for HIV-1 prevention
Current Opinion in HIV and AIDS, 2015Preexposure prophylaxis (PrEP) with daily Truvada has demonstrated clinical efficacy against HIV-1 acquisition that correlates with high adherence. Long-acting antiretroviral drugs offer an alternative to daily regimens and may improve PrEP adherence.
Chasity D, Andrews, Walid, Heneine
openaire +2 more sources
An evaluation of cabotegravir for HIV treatment and prevention
Expert Opinion on Pharmacotherapy, 2020Introduction: Oral pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) represent the cornerstones of HIV infection prevention and treatment. However, despite their high efficacy, the need to take daily oral pill(s) negatively impacts long-term patient adherence.
Canetti D., Spagnuolo V.
openaire +2 more sources
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +2 more sources
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +2 more sources
AIDS
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence ...
Emma, Rubenstein +16 more
openaire +2 more sources
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence ...
Emma, Rubenstein +16 more
openaire +2 more sources
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
New England Journal of Medicine, 2021Raphael J Landovitz +2 more
exaly